You are here: Home ยป Archives for NASDAQ

AI-first Zoom Docs debuts on Zoom Workplace, enhancing meeting effectiveness and transforming team collaboration, document creation, and project planning

  • Optimize collaboration across Zoom Workplace with next–gen Zoom Docs; transform content from Zoom Meetings into actionable documents with AI Companion
  • Zoom Docs’ AI–first customizable design easily adapts to team and project needs, including documents, wikis, and tables, providing a single place to manage work

SAN JOSE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) announced the rollout of Zoom Docs, its AI–first collaborative docs solution, starting today. Zoom Docs is powered by Zoom AI Companion, the company’s generative AI assistant available at no additional cost*, to help drive productivity and seamless collaboration throughout Zoom Workplace.

“Zoom Docs is our first Zoom Workplace product with generative AI built in from the ground up; it effortlessly transforms information from Zoom Meetings into actionable documents and knowledge bases, so teams can stay focused on meaningful work,” said Smita Hashim, chief product officer at Zoom. “Zoom Docs is included at no additional cost with Zoom Workplace paid licenses, creating even more value for our customers. With AI Companion available every step of the way, Zoom Docs is purpose–built to empower people to ‘work happy’ and give them more time back in their day.”

Zoom Docs transforms team collaboration
Zoom Docs can help solve critical challenges facing modern workforces, including time wasted on repetitive tasks, information overload, and facilitation of cross–functional alignment. By utilizing Zoom AI Companion to convert meeting outcomes into actionable documents, Zoom Docs can jumpstart content creation and adapt to different individual and team needs to help boost workers’ productivity.

Zoom Docs’ AI–first capabilities help Zoom Workplace users make teamwork more collaborative and effective, optimize productivity by keeping information organized, and reduce silos by empowering teams to communicate and share information more fluidly. Potential use cases for Zoom Docs include:

  • Meeting collaboration: Zoom Docs simplifies meeting collaboration with AI Companion by transforming meeting content into meaningful documents, centralizing meeting summaries with meeting docs, and facilitating co–editing on docs within meetings.
  • Business documents: Whether creating content, business proposals, or reports, AI Companion for Zoom Docs makes content generation, revision, summarization, and translation easy for global teams.
  • Project planning: Planning complex projects can be messy. Zoom Docs can help with time–saving templates for project briefs and tracking for a variety of use cases like product launches, marketing campaigns, and event management, consolidating project–related materials, and improving visibility across progress tracking, status updates, and timelines.
  • Information hub: Useful for knowledge–base creation, team onboarding, and goal tracking, users can build robust wikis for a single source of information.

Additional AI–first capabilities help teams do their best work
With the power of AI Companion, Zoom Docs simplifies work and brings information together for optimal results.

  • Turn AI Companion meeting summaries into easily editable docs, freeing up time spent on note–taking and manually copying notes into a shared document with templates for one–on–ones, stand–up meetings, brainstorming, project updates, discussions, Q&As, customer success, user feedback, and more.
  • Generate content based on AI Companion meeting transcripts. Use custom or preset commands or queries with AI Companion to further create and revise content.
  • Revise and summarize content such as articles, plans, and outlines, change tone and style, catch grammatical and spelling errors, and translate content into nine languages (with support for additional languages planned) for multilingual teams with AI Companion.

Maximize meeting effectiveness to drive better outcomes
Meetings are core to Zoom Workplace, and Zoom Docs builds on that experience by enhancing collaboration before, during, and after meetings, empowering users to stay more aligned and achieve better results.

  • Start and schedule meetings from a Zoom Doc to connect with colleagues and quickly streamline workflows.
  • Create, share, and co–edit docs during meetings. Meeting attendees can follow along with the presenter, co–edit, and comment on the doc in real time without leaving the meeting window. Attendees on mobile devices can view in–meeting doc collaboration without signing in.
  • Create an editable and shareable doc that includes relevant meeting information from a meeting in a customizable format.
  • Streamline permission sharing to reduce time spent granting access to docs with bulk permission settings for meeting attendees, and the ability to grant temporary access to meeting attendees to collaborate during the meeting. Users can also share Zoom Docs in Team Chat channels and with individuals in specific chats directly from Zoom Docs.
  • Share docs across Zoom Workplace via Zoom Team Chat or Zoom Mail or invite colleagues to collaborate live in Zoom Meetings to streamline editing.

Get work done in one place for better results
Adapt docs to different individual and team needs to keep collaboration fluid and information organized.

  • Customize docs with content blocks for texts, tables, images, charts, and more to help increase efficiency and reduce information management across multiple apps. Add data tables for team collaboration and planning to track assignments and projects. Add checklists, images, videos, and callouts to make the doc more engaging, and utilize the multi–column layout for greater flexibility in organizing content.
  • Embed content from across Zoom Workplace and third parties like Zoom Whiteboard, Google Drive, Figma, X, and YouTube to make information centrally accessible.
  • Stay organized by starring frequently used docs or quickly filtering docs by author for quick access.

Optimize team collaboration
Reduce silos and keep collaborators informed, connected, and aligned.

  • Keep an eye on progress using tables, checklists, and trackers for activities, due dates, status, and assigned owners, with various views like Kanban boards, calendars, and galleries.
  • Organize team documents in dedicated wikis to provide central locations for shared information.
  • Group, filter, sort, and search data tables to easily visualize information and quickly locate the needed data.
  • Edit concurrently with up to 100 users in a single Zoom Doc, and tag teammates in edits and comments.
  • Quickly add, remove, and change permissions for internal teammates and external users to confidently share and collaborate on a doc’s contents.

Zoom Docs with AI Companion is included with all paid Zoom Workplace plans*. Basic (free) users can create up to 10 shared docs and unlimited personal docs without AI Companion but can upgrade to Zoom Workplace Pro, Business, or Enterprise plans for access to AI Companion capabilities across Zoom Workplace, including Docs. Account owners and admins may enable or disable AI Companion for Zoom Docs.

Zoom Docs is available beginning today for users of the Zoom Workplace app, version 6.1.6 or later, which can be downloaded from the Zoom website, and users can also access Zoom Docs from the Docs web homepage or the Zoom Web App.

*Note: AI Companion is included at no additional cost with the paid services assigned to Zoom accounts. AI Companion, including AI Companion capabilities in Zoom Docs, may not be available for all regions and industry verticals.

About Zoom
Zoom’s mission is to provide one platform that delivers limitless human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer care teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations
Lacretia Nichols
press@zoom.us


GLOBENEWSWIRE (Distribution ID 9198845)

Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting – Key SABRE Update Also Expected

JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting which will be held on September 27–30, 2024 in Toronto, ON, Canada.

EB613 is being developed as the first once–daily oral anabolic (bone forming) PTH(1–34) mini tablet therapy for post–menopausal women with high risk osteoporosis. It is estimated that 50 percent of women and 20 percent of men over the age of 50 are at risk of a fragility fractures and approximately 1 in 5 adults will die within the year following a hip fracture. Post menopausal osteoporosis afflicts more women than cancer and cardiovascular disease and is a serious health concern for an estimated 200 million women globally.

“Available injectable anabolic treatments, while efficacious and recommended across medical guidelines, unfortunately do not provide a viable solution for most women with high–risk osteoporosis requiring an anabolic intervention. Our EB613 program is dedicated to address the treatment chasm in current osteoporosis care and hopefully present a treatment for the majority of women to adequately manage their post–menopause bone health with a simple once daily tablet treatment. Importantly, we look forward to the SABRE (Study to Advance BMD as a Regulatory Endpoint) UPDATE at the ASBMR 2024 meeting. On March 26th 2024, Entera echoed the ASBMR announcement that the U.S. Food and Drug Administration (FDA) had communicated to SABRE that a ruling to qualify bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti–osteoporosis drugs would be provided within 10 months. The proposed registrational Phase 3 study for EB613, is designed to meet the quantitative BMD thresholds proposed by SABRE,” said Miranda Toledano, Chief Executive Officer at Entera.

Abstract Title:  3079 – EB613 (Oral PTH(1–34) Tablets) Shows Differentiated Pharmacokinetic Profile From Forteo – New Results from Phase 1b Open–Label Study
Presentation Number:  Sat–LB 589
Session Date/Time: Saturday, September 28, 2024, 2:15 – 3:45 PM 

SABRE Project Update

Speakers: Dennis M. Black , PhD, University of California, United States; Theresa E. Kehoe , MD, CDER/FDA, United States

Session Date / Time: Sunday September 29, 2024 9:45 – 10:45 AM

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline includes five differentiated, first–in–class oral peptide programs, expected to enter the clinic (Phase 1 to Phase 3) by 2025. The Company’s most advanced product candidate, EB613 (oral PTH (1–34)), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis, with no prior fracture. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s expectations regarding licensing, business transactions and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statements Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as the company’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9197414)

Cellebrite Appoints Renowned Cybersecurity Expert Sigalit Shavit as Chief Information Officer

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the appointment of Sigalit Shavit as Chief Information Officer (CIO) who begins her role today, August 1, 2024.

Shavit joins the Company’s Leadership Team, bringing with her more than 30 years of experience to Cellebrite’s information technology and security team. In this newly established position that reports to CEO Yossi Carmil, Shavit will play a pivotal role in scaling the Company’s ability to innovate and support customers as they strive to continue accelerating justice around the globe.

Shavit joins Cellebrite at a time when the Company’s technical innovation and infrastructure is paramount to supporting customers to stay ahead of the growing sophistication of criminals and the ever–increasing growth of digital evidence. She will focus on ensuring that Cellebrite’s information technology and security organizations continue supporting the day–to–day needs of the business, responding decisively to ever–evolving cyber threats, leveraging AI and accelerating innovation.

“Sigalit’s expertise in information technology and security and enabling innovation for enterprise SaaS companies, elevates Cellebrite’s ability to advance its mission of accelerating justice,” said Cellebrite CEO Yossi Carmil. “We are fortunate to gain both her knowledge and leadership, which allows us to better serve our customers and employees.”

Named one of the Top 25 Women Leaders in Cybersecurity in multiple publications, Shavit has held CIO and COO roles with FedEx Express, ECI Telecom, CyberArk and most recently KTrust. During her tenure with CyberArk, she played a critical role through its transformation to an enterprise–grade cloud/SaaS company.

“It is a great honor to be here and lead a team that empowers and propels Cellebrite and its customers forward,” Shavit said. “I am passionate about my team’s significant mission of harnessing a clear, modern digital strategy and solutions to make an impact on efficiency and accelerating innovation.”

About Cellebrite 

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

Media 
Victor Ryan Cooper 
Sr. Director of Corporate Communications + Content Operations 
Victor.cooper@cellebrite.com 
+1 404.804.5910 

Investor Relations 
Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e4793d6b–ce54–4dd5–af87–642468ab62e7


GLOBENEWSWIRE (Distribution ID 9195919)

Zoom to Release Financial Results for the Second Quarter of Fiscal Year 2025

SAN JOSE, Calif., July 31, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2025 on Wednesday, August 21, 2024, after the market closes.

A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.us. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom’s mission is to provide one platform that delivers limitless human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer care teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
press@zoom.us

Investor Relations
Charles Eveslage
Head of Investor Relations for Zoom
investors@zoom.us


GLOBENEWSWIRE (Distribution ID 9196755)

DigiAsia Corp. Forms AI Focused Strategic Advisory Board and Appoints Gulzar Azad as a Strategic Advisor

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, today announced that Gulzar Azad, an accomplished technology leader and entrepreneur, is DigiAsia's first appointee as a strategic advisor to its recently established AI strategic advisory board. DigiAsia’s formation of an advisory board serves a critical purpose in navigating the trajectory of the Company as it rapidly introduces AI technology and capabilities to provide efficiency to enterprise clients in Indonesia at scale. Mr. Azad’s motivation to democratize technology through innovation will significantly benefit DigiAsia's initiatives to build its AI infrastructure and the AI as a Service business.

Mr. Azad currently serves in an advisory role of Health AI and population–scale projects at Google UK and is a Google veteran, having led several early initiatives for product partnerships in India and APAC since 2007. Additionally, Mr. Azad’s experience includes contributions to launch mobile search in India of Android and pioneered strategic projects for high–speed connectivity and software defined networks for Telecom operators.

Prashant Gokarn, CEO of DigiAsia, commented, “We are thrilled to welcome Gulzar to our newly formed AI driven advisory team. His vision and experience in the technology sector perfectly aligns with our goals to expand DigiAsia’s AI capabilities across our SME ecosystem while concurrently making AI more accessible to drive further economic growth in Indonesia. His insights will be invaluable as we continue to innovate and grow DigiAsia’s presence in AI.”

Gulzar Azad added, “I am excited to support DigiAsia in this new capacity as my history and close experience with advancing technology equity and creating distributed architectures to benefit the broader ecosystem is complementary to management’s mission to drive commerce growth across Indonesia and its trading partners in Southeast Asia. Together, we will work towards democratizing AI infrastructure, ensuring it benefits a broader range of stakeholders and fosters innovation across various sectors.”

About DigiAsia

DigiAsia is a leading Fintech as a Service (FaaS) provider operating a B2B2X model offering its complete Fintech solution in emerging markets. DigiAsia’s fintech architecture offers small and medium business enterprises (SMEs) comprehensive embedded finance APIs to streamline processes across the commerce value chain of distributors and customers. DigiAsia’s embedded fintech solutions equally address democratizing digital finance access that supports financial inclusion of underbanked merchants and consumers in emerging markets resulting in growth for enterprise business. The suite of B2B2X solutions provided by DigiAsia include, but are not limited to, cashless payments, digital wallets, digital banking, remittances and banking licenses. DigiAsia has recently established a strategic initiative to develop its embedded FaaS enterprise solution with AI capabilities in Southeast Asia, India, and the Middle East, with plans for global expansion. For more information visit: Corporate website here or Investor website here.

Forward–Looking Statements:

This press release may contain forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward–looking statements. All statements other than statements of historical fact are statements that may be deemed forward–looking statements. These forward–looking statements including, but not limited to, statements concerning DigiAsia and the Company’s operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. DigiAsia cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world including those discussed in DigiAsia’s Form 20–F under the headings “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward–looking statements are applicable only as of the date it is made and DigiAsia specifically disclaims any obligation to maintain or update the forward–looking information, whether of the nature contained in this release or otherwise, in the future.

DigiAsia Company Contact:

Subir Lohani

Chief Financial Officer and Chief Strategy Officer

646–480–0142

Investor Contact:

MZ North America

Email: FAAS@mzgroup.us


GLOBENEWSWIRE (Distribution ID 9195282)

Nyxoah Publiera ses Résultats Financiers pour le Deuxième Trimestre Et le Premier Semestre 2024 le 6 Août 2024

Nyxoah Publiera ses Résultats Financiers pour le Deuxième Trimestre Et le Premier Semestre 2024 le 6 Août 2024

Nyxoah Publiera ses Résultats Financiers pour le Deuxième Trimestre Et le Premier Semestre 2024 le 6 Août 2024

Mont–Saint–Guibert, Belgique – 29 juillet 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La Société a annoncé aujourd'hui qu’elle publiera ses résultats financiers pour le deuxième trimestre et le premier semestre 2024 le 6 août 2024, après la clôture du marché. Le management de la Société organisera une conférence téléphonique pour discuter ses résultats financiers le même jour, à 22h30 CET / 16h30 ET.

La retransmission de la conférence téléphonique sera accessible sur la page Investor Relations du site web de Nyxoah ou par le biais de ce lien : Nyxoah's Q2 2024 earnings call webcast. Pour ceux qui n'ont pas l'intention de poser une question au Management, la Société recommande d'écouter la webdiffusion.

Si vous avez l'intention de poser une question, veuillez utiliser le lien suivant : Nyxoah’s Q2 2024 earnings call. Après l'inscription, un courriel sera envoyé, comprenant les détails de la connexion et un code d'accès unique à la conférence téléphonique nécessaire pour rejoindre l'appel en direct. Pour s'assurer que vous êtes connecté avant le début de la conférence, la Société suggère de s'inscrire au moins 10 minutes avant le début de l'appel.

Le webcast archivé pourra être réécouté peu après la clôture de la conférence.

À propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

Pour plus d’informations, visitez http://www.nyxoah.com/

Attention – Marquage CE depuis 2019. Dispositif expérimental aux États–Unis. Limité par la loi fédérale américaine à une utilisation expérimentale aux États–Unis.

Déclarations Prospectives

Certaines déclarations, croyances et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la société ou, le cas échéant, des administrateurs ou de la direction de la société concernant le système Genio®, les études cliniques prévues et en cours sur le système Genio®, les avantages potentiels du système Genio® ; les objectifs de Nyxoah en ce qui concerne le développement, la voie réglementaire et l'utilisation potentielle du système Genio® ; l'utilité des données cliniques pour l'obtention éventuelle de l'approbation du système Genio® par la FDA ; et les résultats d'exploitation, la situation financière, les liquidités, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prévisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent matériellement de ceux exprimés ou sous–entendus dans les déclarations prévisionnelles. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence négative sur les résultats et les effets financiers des plans et des événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section ” Facteurs de risque ” du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2023, déposé auprès de la Securities and Exchange Commission (” SEC “) le 20 mars 2024, et des rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent de manière significative de tout développement anticipé. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une déclaration selon laquelle ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements peuvent ne pas être représentatifs des résultats ou développements des périodes futures. Aucune déclaration ou garantie n'est donnée quant à l'exactitude ou à la sincérité de ces déclarations prospectives. En conséquence, la société décline expressément toute obligation ou tout engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement des attentes ou d'un changement des événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont basées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces énoncés prospectifs sont exemptes d'erreurs et n'acceptent aucune responsabilité quant à l'exactitude future des énoncés prospectifs contenus dans le présent communiqué de presse ou à la survenance réelle des développements prévus. Vous ne devriez pas accorder une confiance excessive aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Media
Belgique / France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/ Allemagne
MC Services – Anne Hennecke
anne.hennecke@mc–services.eu

GLOBENEWSWIRE (Distribution ID 1000983944)

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024

Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024

Mont–Saint–Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q2 2024 earnings call. After registering, an email will be sent, including dial–in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc–services.eu

Attachment


GLOBENEWSWIRE (Distribution ID 1000983944)

Gravity Announced Cute and Dark Puzzle Adventure ‘PIGROMANCE’ Official Launch on Steam!

– Award Winning Gameplay and Creativity from Various Global Game Awards
– Now Celebrating Official Launch with 20% Discount

SEOUL, South Korea, July 25, 2024 (GLOBE NEWSWIRE) — Global game developer and publisher Gravity announced the official release of the puzzle adventure ‘PIGROMANCE’ on Steam on July 25th.

The puzzle adventure ‘PIGROMANCE’ elaborates the story of a pig born with the fate of becoming a sausage, escaping from a sausage factory to find its love. Players can enjoy solving puzzles while escaping from the Cuttingman and navigating the dangerous obstacles lurking throughout the sausage factory. ‘PIGROMANCE’ features cute chibi graphics with contrasting vibes of dark lighting, gruesome visual and sound effects, and spooky BGMs that almost resemble disturbing fairy tales.

Even before its official release, ‘PIGROMANCE’ was recognized for its remarkable playability and fresh concept by winning various awards, including the Excellence Prize in the 2024 INDIE CRAFT, MWU(Made With Unity) KR 2023 ‘Best Indie’ Category, 1st place in the 2022 Level Up Showcase, 2nd place for 2022 G–STAR Indie Awards, and Silver Award at Global Indie Game Development Contest 2020. ‘PIGROMANCE’ was praised at various game events for its fresh storytelling and developing suspense.

The official launch version is now available for play on Steam supporting 9 different languages, including Korean, English, Japanese, Simplified Chinese, and French. Gravity is offering a 20% discount until August 7th to celebrate the official release.

“PIGROMANCE is a game that has proven its playability through multiple game awards and was positively commented on and earned a positive reputation from players on–site. Anyone, including players who prefer casual games, can play ‘PIGROMANCE’,” said Yoo Jun, a lead manager of Gravity’s console game business department. “We have brought up the level of the game’s completion by reflecting on the priceless feedback of players, and the game features catchy art styles and storylines, which will feel quite different from many other casual games. We appreciate all the players waiting for the official release.”

[Official Homepage of Gravity] http://www.gravity.co.kr
[Official Steam Store Page of PIGROMANCE] https://store.steampowered.com/app/1362120/_/
[Official Homepage of PIGROMANCE] https://www.pigromance.com/default/

– Inquiry: Gravity 2 Business unit
Sang–min Park / smpark@gravity.co.kr

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/59ea75da–e656–4657–8eae–77ec1f032a4d


GLOBENEWSWIRE (Distribution ID 9193301)

Gravity gibt die offizielle Lancierung des schaurig-schönen Puzzle- und Adventure-Spiels „PIGROMANCE“ auf Steam bekannt!

– Für Gameplay und Kreativität mit diversen Global Game Awards ausgezeichnet
– Zum offiziellen Start gibt es nun 20 % Rabatt

SEOUL, Südkorea, July 25, 2024 (GLOBE NEWSWIRE) — Der internationale Game–Entwickler und –Publisher Gravity hat den offiziellen Release des Puzzle– und Adventure–Spiels „PIGROMANCE“ am 25. Juli auf Steam angekündigt.

Das Puzzle– und Adventure–Spiel „PIGROMANCE“ erzählt die Geschichte eines Schweins, dessen Schicksal es ist, zu Wurst verarbeitet zu werden, stattdessen aber aus einer Wurstfabrik ausbricht, um Liebe zu finden. Bei dem Versuch, dem Schlachter zu entkommen und die Gefahren zu meistern, die in der Wurstfabrik lauern, gilt es, Rätsel lösen. „PIGROMANCE“ verbindet niedliche Chibi–Grafik mit dunkler Beleuchtung, schaurigen Bild– und Soundeffekten und gruseligen Hintergrundmelodien, die die Erinnerung an unheimliche Märchen wachrufen.

Schon vor der eigentlichen Veröffentlichung wurde „PIGROMANCE“ für seine bemerkenswerte Spielbarkeit und sein ungewöhnliches Konzept mit verschiedenen Preisen ausgezeichnet, darunter der Excellence Prize in der INDIE CRAFT 2024, MWU (Made With Unity) KR 2023 „Best Indie“–Kategorie, der erste Platz beim Level Up Showcase 2022, der zweite Platz bei den G–STAR Indie Awards 2022 und der Silver Award beim Global Indie Game Development Contest 2020. „PIGROMANCE“ wurde auf verschiedenen Game–Events für seine erfrischende Erzählweise und den sich aufbauenden Spannungsbogen positiv bewertet.

Die offizielle Launch–Version ist jetzt auf Steam verfügbar und unterstützt 9 verschiedene Sprachen, darunter Koreanisch, Englisch, Japanisch, vereinfachtes Chinesisch und Französisch. Anlässlich des offiziellen Releases bietet Gravity bis zum 7. August einen Rabatt von 20 % an.

„PIGROMANCE hat seine Spielbarkeit bereits durch mehrere Game Awards unter Beweis gestellt und wurde von den Spielern vor Ort positiv bewertet und gelobt. Jeder, auch die Spieler, die Casual Games bevorzugen, können ‚PIGROMANCE‘ spielen“, kommentiert Yoo Jun, ein leitender Manager der Abteilung für Konsolenspiele bei Gravity. „Wir konnten die Qualität des Spiels aufgrund des unbezahlbaren Feedbacks der Spieler verbessern. Außerdem zeichnet sich das Spiel durch einen eingängigen Grafikstil und eine Storyline aus, die sich von vielen anderen Casual Games unterscheidet. Wir wissen das Interesse innerhalb der Gaming–Community zu schätzen, die dem offiziellen Release entgegenfiebert.“

[Offizielle Homepage von Gravity] http://www.gravity.co.kr
[Offizielle Steam Store–Seite von PIGROMANCE] https://store.steampowered.com/app/1362120/_/
[Offizielle Homepage von PIGROMANCE] https://www.pigromance.com/default/

– Anfrage: Gravity 2 Business Unit
Sang–min Park / smpark@gravity.co.kr

Ein Foto zu dieser Meldung ist verfügbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/59ea75da–e656–4657–8eae–77ec1f032a4d


GLOBENEWSWIRE (Distribution ID 9193300)

Gravity annonce le lancement officiel du sombre jeu d’aventure et de puzzle « PIGROMANCE » sur Steam !

– Une créativité et un gameplay récompensés par divers prix vidéoludiques à l’échelle mondiale
– À l’occasion du lancement officiel, actuellement disponible avec une remise de 20 %

SÉOUL, Corée du Sud, 25 juill. 2024 (GLOBE NEWSWIRE) — Gravity, un éditeur et développeur international de jeux vidéo, annonce la sortie officielle du jeu d’aventure et de puzzle « PIGROMANCE » sur Steam le 25 juillet.

La trame de ce jeu repose sur l’histoire d’un cochon dont le destin funeste est de finir en saucisse, et qui s’échappe de l’usine de saucisses pour rencontrer l’amour. Les joueurs peuvent s’amuser à résoudre des puzzles tout en fuyant le Découpeur, ou à contourner les dangereux obstacles semés de part et d’autre de l’usine de saucisses. « PIGROMANCE » se distingue par des effets de contraste entre ses mignons graphismes de style chibi et son jeu de lumières plus sombre, ses images macabres, ses sons de même tonalité et sa musique de fond angoissante qui rappelle les plus inquiétants contes de fées.

Le concept novateur et la jouabilité remarquable de « PIGROMANCE » ont été récompensés par divers prix en amont de sa sortie officielle. Le jeu a notamment décroché le prix d’excellence lors de l’édition 2024 du festival INDIE CRAFT. Il s’est également distingué dans la catégorie « meilleur jeu indépendant » au MWU (Made With Unity) 2023 en Corée du Sud et a obtenu la première place au Showcase Level Up 2022, la deuxième place aux G–STAR Indie Awards 2022, mais aussi la médaille d’argent au Global Indie Game Development Contest 2020. Le style narratif de « PIGROMANCE » et son suspense croissant ont reçu des éloges lors de nombreux événements vidéoludiques.

La version du lancement officiel est disponible dès à présent sur Steam et jouable en 9 langues, dont le coréen, l’anglais, le japonais, le chinois simplifié et le français. Pour fêter son lancement officiel, Gravity propose une réduction de 20 % jusqu’au 7 août.

« PIGROMANCE » a prouvé sa jouabilité à travers de nombreuses récompenses vidéoludiques, et le jeu a reçu des commentaires positifs des joueurs sur place, gagnant ainsi une bonne réputation. Pour Yoo Jun, l’un des responsables en chef du département des jeux sur console de Gravity, « Tout le monde peut jouer à PIGROMANCE, y compris les amateurs de jeux grand public. Nous avons amélioré le niveau final à l’appui des précieux retours des joueurs, et le jeu présente à la fois des arcs narratifs et des styles artistiques accrocheurs qui lui confèrent une certaine singularité par rapport à de nombreux autres jeux grand public. Nous sommes reconnaissants envers tous les joueurs qui en attendent la sortie officielle. »

[Site officiel de Gravity] http://www.gravity.co.kr
[Page officielle de PIGROMANCE sur la boutique Steam] https://store.steampowered.com/app/1362120/_/
[Site officiel de PIGROMANCE] https://www.pigromance.com/default/

– Pour toute question : Gravity 2 Business unit
Sang–min Park / smpark@gravity.co.kr

Une photo annexée au présent communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/59ea75da–e656–4657–8eae–77ec1f032a4d


GLOBENEWSWIRE (Distribution ID 9193300)